Alogliptin is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005.
|Appearance||almost white crystalline powder|
Send us your enquiry for Alogliptin. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Alogliptin email us and we will include your contribution on the website.